Skip to main content
SpringerLink
Log in

Perioperative Management of Gastric Cancer Patients Treated With (Sub)Total Gastrectomy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Lessons Learned

  • Peritoneal Surface Malignancy
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The PERISCOPE I study was designed to assess the safety and feasibility of (sub)total gastrectomy, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin and docetaxel for gastric cancer patients who have limited peritoneal dissemination. The current analysis investigated changes in perioperative management together with their impact on postoperative outcomes.

Methods

Patients with resectable gastric cancer and limited peritoneal dissemination were administered (sub)total gastrectomy, CRS, and HIPEC with oxaliplatin (460 mg/m2) and docetaxel (escalating scheme: 0, 50, 75 mg/m2). Of the 25 patients who completed the study protocol, 14 were treated in the dose-escalation cohort and 11 were treated in the expansion cohort (to optimize perioperative management).

Results

A significant proportion of the patients in the dose-escalation cohort (n = 7, 50%) had ileus-related complications. In this cohort, enteral nutrition was started immediately after surgery at 20 ml/h, which was increased on day 1 to meet nutritional needs. In the expansion cohort, enteral nutrition was administered at 10 ml/h until day 3, then restricted to 20 ml/h until day 6, supplemented with total parenteral nutrition to meet nutritional needs. Ileus-related complications occurred for two patients (18%) of the expansion cohort. The intensive care unit (ICU) readmission rate decreased from 50 (n = 7) to 9% (n = 1; p = 0.04).

Conclusion

The implementation of a strict nutritional protocol during the PERISCOPE I study was associated with a decrease in postoperative complications. Based on these results, a perioperative care path was described for the gastric cancer HIPEC patients in the PERISCOPE II study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.

    Article  Google Scholar 

  2. Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378: 230–40.

    Article  Google Scholar 

  3. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245:104–9.

    Article  Google Scholar 

  4. Glehen O, Passot G, Villeneuve L, Vaudoyer D, Bin-Dorel S, Boschetti G, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014;14:183.

    Article  Google Scholar 

  5. Koemans WJ, van der Kaaij RT, Boot H, Buffart T, Veenhof A, Hartemink KJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination: the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer. 2019;19:420.

    Article  CAS  Google Scholar 

  6. Rau B, Brandl A, Piso P, Pelz J, Busch P, Demtroder C, et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23:11–22.

    Article  Google Scholar 

  7. Rihuete Caro C, Manzanedo I, Pereira F, Carrion-Alvarez L, Serrano A, Perez-Viejo E. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. Eur J Surg Oncol. 2018;44:1805–10.

    Article  Google Scholar 

  8. Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028–40.

    Article  CAS  Google Scholar 

  9. ill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692–8.

    Article  Google Scholar 

  10. Wu Z, Li Z, Ji J. Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in advanced gastric cancer. Transl Gastroenterol Hepatol. 2016;1:63.

    Article  Google Scholar 

  11. Raspe C, Flother L, Schneider R, Bucher M, Piso P. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2017;43:1013–27.

    Article  CAS  Google Scholar 

  12. Webb CA, Weyker PD, Moitra VK, Raker RK. An overview of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for the anesthesiologist. Anesth Analg. 2013;116:924–31.

    Article  Google Scholar 

  13. Cooksley TJ, Haji-Michael P. Postoperative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). World J Surg Oncol. 2011;9:169.

    Article  Google Scholar 

  14. Bell JC, Rylah BG, Chambers RW, Peet H, Mohamed F, Moran BJ. Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience. Ann Surg Oncol. 2012;19:4244–51.

    Article  Google Scholar 

  15. De Somer F, Ceelen W, Delanghe J, De Smet D, Vanackere M, Pattyn P, Mortier E. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int. 2008;28:61–6.

    Article  Google Scholar 

  16. Padmakumar AV. Intensive care management of patient after cytoreductive surgery and HIPEC: a concise review. Indian J Surg Oncol. 2016;7:244–8.

    Article  CAS  Google Scholar 

  17. van der Kaaij RT, Braam HJ, Boot H, Los M, Cats A, Grootscholten C, et al. Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): rationale and design of the PERISCOPE study. JMIR Res Protoc. 2017;6:136.

    Article  Google Scholar 

  18. van der Kaaij RT, Wassenaar ECE, Koemans WJ, Sikorska K, Grootscholten C, Los M, et al. Treatment of PERItoneal disease in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy (HIPEC): initial results of the PERISCOPE I. Br J Surg. 10.1002/bjs.11588 2020.

    Article  PubMed  Google Scholar 

  19. ClinicalTrials.gov. Identifier: NCT03348150. Gastrectomy + cytoreductive surgery + HIPEC for gastric cancer with peritoneal dissemination. (PERISCOPE II). Retrieved 1 January 2020 at https://ClinicalTrials.gov/show/NCT03348150

  20. U.S. Department of Health and Human Services NCI. Common terminology criteria for adverse events (CTCAE). 2009; https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.

  21. Roza AM, Shizgal HM. The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass. Am J Clin Nutr. 1984;40:168–82.

    Article  CAS  Google Scholar 

  22. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.

    Article  Google Scholar 

  23. Shannon NB, Tan GHC, Chia CS, Soo KC, Teo MC. Does having a gastrectomy delay time to feeding and prolong hospital stay in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Int J Hyperthermia. 2018;34:518–23.

    Article  CAS  Google Scholar 

  24. Leijte GP, Custers H, Gerretsen J, Heijne A, Roth J, Vogl T, et al. Increased plasma levels of danger-associated molecular patterns are associated with immune suppression and postoperative infections in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Front Immunol. 2018;9:663.

    Article  Google Scholar 

  25. Klein CJ, Stanek GS, Wiles CE III. Overfeeding macronutrients to critically ill adults: metabolic complications. J Am Diet Assoc. 1998;98:795–806.

    Article  CAS  Google Scholar 

  26. Zhao XF, Wu N, Zhao GQ, Liu JF, Dai YF. Enteral nutrition versus parenteral nutrition after major abdominal surgery in patients with gastrointestinal cancer: a systematic review and meta-analysis. J Investig Med 2016;64:1061–74.

    Article  Google Scholar 

  27. Shime N, Lee M, Hatanaka T. Cardiovascular changes during continuous hyperthermic peritoneal perfusion. Anesth Analg. 1994;78:938–42.

    Article  CAS  Google Scholar 

  28. Schmidt C, Creutzenberg M, Piso P, Hobbhahn J, Bucher M. Perioperative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia. 2008;63:389–95.

    Article  CAS  Google Scholar 

  29. Creagh-Brown BC, De Silva AP, Ferrando-Vivas P, Harrison DA. Relationship between peak lactate and patient outcome following high-risk gastrointestinal surgery: influence of the nature of their surgery: elective versus emergency. Crit Care Med. 2016;44:918–25.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

    W. J. Koemans MD, R. T. van der Kaaij MD, PhD, A. A. F. A. Veenhof MD, PhD, K. J. Hartemink MD, PhD & J. W. van Sandick MD, PhD

  2. Department of Anesthesiology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

    A. Houwink MD & C. Hahn MD, PhD

  3. Department of Intensive Care Medicine, The Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

    A. Houwink MD

  4. Department of Dietetics, The Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

    E. C. E. Wassenaar MD & D. Boerma MD, PhD

  5. Clinical Perfusion, Heartbeat, Eemnes, The Netherlands

    O. Imhof

  6. Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands

    M. G. Brandt & M. P. Ariëns

Authors
  1. W. J. Koemans MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Houwink MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. T. van der Kaaij MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. C. E. Wassenaar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Boerma MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Hahn MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O. Imhof
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. G. Brandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. P. Ariëns
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. A. F. A. Veenhof MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K. J. Hartemink MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J. W. van Sandick MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. W. van Sandick MD, PhD.

Ethics declarations

Disclosure

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koemans, W.J., Houwink, A., van der Kaaij, R.T. et al. Perioperative Management of Gastric Cancer Patients Treated With (Sub)Total Gastrectomy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Lessons Learned. Ann Surg Oncol 28, 4647–4654 (2021). https://doi.org/10.1245/s10434-020-09465-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-09465-8

Search

Navigation